New drug cocktail shows promise for lung cancer patients

NCT ID NCT05519865

Completed Disease control Sponsor: Chipscreen Biosciences, Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial tested a combination of two drugs, tucidinostat and tislelizumab, as a first treatment for people with a type of advanced lung cancer that has a specific marker (PD-L1 positive). The study involved 118 participants and aimed to see if the combo could delay cancer growth. It is a randomized, double-blind trial, meaning neither patients nor doctors knew who got the combo versus a control.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Tucidinostat (Chidamide) and Tislelizumab
What this could lead to: If successful, this combination could offer a new first-line treatment option for people with PD-L1 positive advanced lung cancer, potentially slowing tumor growth.
What could go wrong: This is an early-phase (phase 2) trial with only 118 participants, so results may not apply to everyone. The drugs may cause side effects or not work better than existing treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NON-SMALL CELL LUNG CANCER

Contacts and locations

Locations

Shanghai Pulmonary Hospital

Shanghai, Shanghai Municipality, 200433, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.